Current allogeneic cell therapies require donor-patient matching, which can be a barrier to access and timely treatment. Existing therapies may also have limitations in scalability and cost-effectiveness, hindering widespread availability for patients with cancer and other critical diseases.

Deverra Therapeutics is developing off-the-shelf, allogeneic cell therapies derived from healthy donor umbilical cord blood, eliminating the need for donor-patient matching. Their platform technology is designed to generate various cell types, creating a diverse pipeline of cell therapies for multiple indications. The company's scalable manufacturing and cryopreservation process enables the delivery of ready-made therapies for immediate, on-demand use. Deverra's lead product, Dilanubicel, is being developed as a non-engrafting adjuvant cell therapy with chemotherapy to enhance remission rates and improve overall survival in AML patients.

Dilanubicel: A stem and progenitor cell therapy in clinical stage for newly diagnosed AML patients.

Unmodified NK cells and myeloid cells: Engineered to fight cancer and boost immunity against viral infections.

Modified NK and myeloid cells: Designed to target blood cancers and solid tumors, used alone or in combination with other cell therapy products.

Scalable manufacturing process: Allows for the generation of hundreds of doses per manufacturing run.

Cryopreservation SOP: Enables off-the-shelf availability and on-demand use.

No genetic modifications of the starting material required for NK cell generation.

Non-viral gene delivery systems: Investigated for modified immune effector cells.

The primary target audience includes patients with AML and other cancers, as well as healthcare providers seeking accessible and cost-effective cell therapy options.